Pharmacy Services, Mayo Clinic, Rochester, MN.
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.
Am J Health Syst Pharm. 2020 Oct 30;77(22):1859-1865. doi: 10.1093/ajhp/zxaa192.
To evaluate the impact of a collaborative intervention by pharmacists and primary care clinicians on total cost of care, including costs of inpatient readmissions, emergency department visits, and outpatient care, at 30, 60, and 180 days after hospital discharge in a population of patients at high risk for readmission due to polypharmacy.
A retrospective study of cost outcomes in a cohort of adult patients discharged from a single institution from July 1, 2013 to March 25, 2016, was conducted. All patients had at least 10 medications listed on their discharge list, including at least 1 drug frequently associated with adverse events leading to hospital readmission. About half of the cohort (n = 496) attended a postdischarge visit involving both a pharmacist and a primary care clinician (a physician, physician assistant, or licensed nurse practitioner); this was designated the pharmacist/clinician collaborative (PCC) group. The remainder of the cohort (n = 500) attended a visit without pharmacist involvement; this was designated as the usual care (UC) group. Costs were compared using a quantile regression to assess the potential heterogeneous impacts of the PCC intervention across different parts of the cost distribution. All outcomes were adjusted for differences in baseline characteristics.
At 30 days post index discharge, there was a significant decrease in total costs in the 10th and 90th cost quantiles in the PCC cohort vs the UC cohort, without a statistically significant decrease in the 25th, 50th or 75th quantiles. The difference was significant in the 75th and 90th quantiles at 60 days and in the 25th, 50th, and 75th quantiles at 180 days. There was a nonsignificant cost reduction in all other quantiles.
Medically complex patients had a significantly lower total cost of care in approximately half of the adjusted cost quantiles at 30, 60, and 180 days after hospital discharge when they had a PCC visit. PCC visits can improve patient clinical outcomes while improving cost metrics.
评估药剂师和初级保健临床医生合作干预对因多种药物治疗而有住院再入院风险的患者出院后 30、60 和 180 天内总医疗成本(包括住院再入院、急诊就诊和门诊护理成本)的影响。
对 2013 年 7 月 1 日至 2016 年 3 月 25 日期间从一家机构出院的成年患者队列的成本结果进行回顾性研究。所有患者出院单上至少列出 10 种药物,其中至少有 1 种药物经常与导致住院再入院的不良事件相关。队列的一半左右(n=496)参加了包括药剂师和初级保健临床医生(医生、医师助理或持牌执业护士)在内的出院后访视;这被指定为药剂师/临床医生协作(PCC)组。队列的其余部分(n=500)参加了没有药剂师参与的访视;这被指定为常规护理(UC)组。使用分位数回归比较成本,以评估 PCC 干预对成本分布不同部分的潜在异质影响。所有结果均根据基线特征的差异进行调整。
在指数出院后 30 天,PCC 队列与 UC 队列在第 10 和第 90 个成本分位数的总费用显著降低,而第 25、第 50 和第 75 个分位数的费用没有显著降低。在第 60 天的第 75 和第 90 分位数和第 180 天的第 25、第 50 和第 75 分位数,差异显著。在所有其他分位数中,成本都有轻微降低。
在出院后 30、60 和 180 天,当患者接受 PCC 访视时,大约一半的调整后成本分位数中,医疗复杂患者的总医疗成本显著降低。PCC 访视可以改善患者的临床结果,同时改善成本指标。